vida: extract claims from 2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis

- Source: inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -81,3 +81,10 @@ Concurrent psychotropic medication use (antidepressants, benzodiazepines) shows
 **Source:** The Lancet 2026, EVOKE/EVOKE+ Phase 3 failure
 
 EVOKE/EVOKE+ Alzheimer's failure provides critical boundary evidence for GLP-1 CNS mechanism specificity. Semaglutide succeeds in addiction (VTA dopamine reward circuits) but fails in neurodegeneration (amyloid/tau pathways), demonstrating that GLP-1 receptor activation produces pathway-specific effects rather than broad neuroprotection. This supports the mesolimbic dopamine mechanism for addiction while ruling out generalized CNS benefit claims.
+
+
+## Extending Evidence
+
+**Source:** NBC News/Pharmacy Times synthesis, April 2026
+
+NBC News synthesis documents GLP-1 evidence across four substance use disorder categories: (1) OUD: liraglutide shows ~40% craving reduction in Phase 2 RCT, semaglutide reduces overdose risk in T2D+OUD comorbid population; (2) Nicotine: exenatide+NRT increases 6-week abstinence, but long-term findings mixed; (3) Cocaine/stimulants: preclinical only (liraglutide reduces methamphetamine intake in rats); (4) Population-level: GLP-1 users with pre-existing SUD show fewer ER visits, hospitalizations, deaths across substance categories (observational data with selection bias concerns). Evidence strength hierarchy: AUD > OUD > nicotine > cocaine. As of April 2026, 33 clinical trials active (15 AUD, 9 nicotine, 4 OUD, 4 cocaine). Critical limitation: all human evidence from patients with comorbid metabolic disease—efficacy without T2D/obesity comorbidity unknown.

domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.m
 scope: causal
 sourcer: Hendershot CS et al.
 supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression"]
+related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
 ---
 
 # Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression
@@ -31,3 +31,10 @@ Meta-analysis confirms semaglutide as best-performing agent for alcohol reductio
 **Source:** Qeadan F et al., Addiction 2025
 
 Real-world observational data from 817,309 AUD patients (5,621 with GLP-1 RA) shows 50% lower alcohol intoxication rates (IRR 0.50, 95% CI 0.40-0.63) over 24 months, consistent with Hendershot RCT findings. Effect maintained across T2DM (IRR 0.51), obesity (IRR 0.58), and combined conditions (IRR 0.58) subgroups. Provides population-scale corroboration of the VTA dopamine mechanism hypothesis, though observational confounding limits causal inference.
+
+
+## Extending Evidence
+
+**Source:** NBC News synthesis + Session 22 Science 2025
+
+The VTA dopamine mechanism is shared across all substance use disorders, not AUD-specific. GLP-1 receptors in ventral tegmental area and nucleus accumbens reduce dopamine surge from substance exposure, attenuating reward salience. This explains why GLP-1 effects extend beyond alcohol to opioids, nicotine, and potentially cocaine. However, Session 22 Science 2025 paper showed VTA dopamine circuits adapt during repeat GLP-1 treatment (mice recover hedonic eating), suggesting efficacy may fade with long-term use for some reward circuits.

entities/health/nct04199728-glp1-oud.md

@@ -0,0 +1,34 @@
+# NCT04199728: GLP-1 Receptor Agonist for Opioid Use Disorder
+
+**Type:** Clinical trial  
+**Phase:** 2  
+**Status:** Active (as of April 2026)  
+**Intervention:** GLP-1 receptor agonist (specific drug not specified in source)  
+**Target:** Opioid Use Disorder (OUD)  
+
+## Trial Context
+
+Part of broader GLP-1 substance use disorder research program. As of April 2026, 4 OUD trials active out of 33 total SUD trials.
+
+## Evidence Base
+
+**Liraglutide OUD data:**
+- ~40% reduction in opioid craving in small randomized double-blind placebo-controlled residential study
+- Phase 2 evidence only
+
+**Semaglutide OUD data:**
+- Significantly reduced opioid overdose risk in 1-year follow-up for patients with comorbid T2D + OUD (real-world observational data)
+- Cannot distinguish causal mechanism from selection effects
+
+**Mechanism:** GLP-1 receptors in ventral tegmental area (VTA) and nucleus accumbens reduce dopamine surge from opioid exposure, attenuating reward salience.
+
+**Critical limitation:** All human evidence from patients with comorbid metabolic disease. Efficacy for OUD without T2D/obesity comorbidity unknown and largely unstudied.
+
+## Timeline
+
+- **2026-04-28** — NBC News synthesis reports Phase 2 evidence for GLP-1 in OUD, no Phase 3 trials completed
+
+## Sources
+
+- NBC News/Pharmacy Times synthesis, April 2026
+- ClinicalTrials.gov NCT04199728

inbox/archive/health/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md

@@ -7,10 +7,13 @@ date: 2026-04-28
 domain: health
 secondary_domains: []
 format: news-analysis
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-03
 priority: medium
 tags: [GLP-1, addiction, opioid-use-disorder, nicotine, cocaine, substance-use-disorder, VTA-dopamine, reward-mechanism]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content